What did the INTerpath-001 trial actually prove?

The Phase 3 trial showed intismeran (Moderna's personalized mRNA neoantigen therapy) combined with Keytruda significantly reduced melanoma recurrence compared to Keytruda alone. This is the first Phase 3 win for ANY individualized neoantigen therapy—validating that custom mRNA vaccines designed from a patient's tumor DNA can improve outcomes in a controlled, large-scale trial.

How is this different from the dog vaccine story?

It's the same fundamental approach—sequence tumor DNA, identify neoantigens, encode them in mRNA—but at pharmaceutical scale with regulatory rigor. Paul Conyngham's n=1 proof-of-concept showed the pipeline was executable by an individual. INTerpath-001 (n=1,137) proves it works in humans under controlled conditions.

What is intismeran and how does it work?

Intismeran (V940/mRNA-4157) is an mRNA-based individualized neoantigen therapy. For each patient: (1) tumor is sequenced to find mutations, (2) up to 34 neoantigens are selected, (3) synthetic mRNA encoding these neoantigens is manufactured, (4) mRNA is administered to train the immune system to recognize and attack cells displaying those specific mutations.

When will this treatment be available?

Merck and Moderna will submit to regulators following data presentation at an upcoming medical conference. FDA priority review could mean approval in 2027 for resected stage IIB-IV melanoma. Broader cancer types (lung, bladder, kidney) are in Phase 2/3 trials now.

What does this mean for DIY approaches?

The science is validated. The pipeline works. But regulatory approval means access through oncologists, not homebrew. The practical impact: within 2-3 years, your doctor may order a tumor biopsy that generates a custom vaccine delivered in weeks—no AlphaFold required on your end.

How much did outcomes improve?

Trial met both primary (recurrence-free survival) and secondary (distant metastasis-free survival) endpoints with 'statistically significant and clinically meaningful improvements' vs. Keytruda alone. Prior Phase 2b data showed 49% reduction in recurrence risk and 59% reduction in distant metastasis risk at 5-year follow-up.

Melanoma has high mutation burden (lots of neoantigens to target), established immunotherapy response (Keytruda already works), and clear adjuvant setting (post-surgery, measurable recurrence endpoint). It's the ideal proving ground for personalized neoantigen vaccines.

What other cancers are being tested?

The INTerpath program includes Phase 2/3 trials in non-small cell lung cancer (NSCLC), bladder cancer, renal cell carcinoma, pancreatic ductal adenocarcinoma, and gastric carcinoma. If melanoma results hold, expect rapid expansion.

Merck-Moderna's mRNA Cancer Vaccine Just Passed Phase 3: What It Means for the DIY Pipeline We Wrote About

By Prahlad Menon Published 2026-08-19 3 min read

Six months ago, we wrote about Paul Conyngham—a Sydney tech entrepreneur who used ChatGPT, AlphaFold, and $3,000 in DNA sequencing to design a personalized mRNA cancer vaccine for his dog Rosie. The tumor shrank 75%. The scientific establishment’s response was measured: interesting proof-of-concept, but n=1 isn’t evidence.

Today, Merck and Moderna announced that the same fundamental approach—personalized mRNA neoantigen therapy—just passed Phase 3.

What Happened

The INTerpath-001 trial tested intismeran (Moderna’s individualized neoantigen therapy, also called V940) combined with Keytruda (pembrolizumab, Merck’s checkpoint inhibitor) against Keytruda alone in 1,137 patients with completely resected stage IIB-IV melanoma.

Results at pre-specified interim analysis:

Primary endpoint met: Statistically significant improvement in recurrence-free survival (RFS)
Key secondary endpoint met: Statistically significant improvement in distant metastasis-free survival (DMFS)
Safety: Consistent with prior studies, no new signals

This is the first time any individualized neoantigen therapy has succeeded in Phase 3. It’s also the first Phase 3 study to show improvement over Keytruda alone in adjuvant melanoma—and Keytruda is already the standard of care.

The Pipeline, Now at Scale

What Paul Conyngham did in his living room with ChatGPT and AlphaFold, Merck and Moderna have industrialized:

Step	DIY (Conyngham)	Pharma (Intismeran)
Tumor sequencing	Commercial lab, ~$3K	Standardized biopsy workflow
Neoantigen selection	Custom ML + pVACtools	Proprietary Moderna algorithms
mRNA design	Manual sequence spec	Automated, up to 34 neoantigens
Manufacturing	University lab favor	Moderna’s mRNA platform
Delivery	Single injection, hopeful	9 doses over ~1 year, controlled
Combination therapy	None	Keytruda (9 cycles)
Outcome measurement	Tumor shrinkage observed	RFS, DMFS, OS (ongoing)

The science is identical. The execution is different. Conyngham proved the pipeline works for a determined individual. INTerpath-001 proves it works at pharmaceutical scale with regulatory rigor.

Why This Matters Beyond Melanoma

Melanoma was chosen strategically:

High mutation burden → more neoantigens to target
Immunotherapy-responsive → Keytruda already demonstrates immune system can control melanoma
Clear adjuvant setting → post-surgery patients with measurable recurrence risk

But Merck and Moderna aren’t stopping at melanoma. The INTerpath program currently includes:

Cancer Type	Trial Phase	Setting
Melanoma (IIB-IV)	Phase 3 ✓	Adjuvant
Non-small cell lung cancer	Phase 3	Adjuvant
Bladder cancer	Phase 2/3	Perioperative
Renal cell carcinoma	Phase 2/3	Adjuvant
Pancreatic adenocarcinoma	Phase 1	Adjuvant
Gastric carcinoma	Phase 1	Perioperative

Nine total trials. Multiple tumor types. Multiple disease stages.

The hypothesis: if personalized neoantigen vaccines work in melanoma, they should work anywhere the immune system can reach—which is most solid tumors.

The 5-Year Data We Already Had

This Phase 3 readout builds on remarkable Phase 2b results from the KEYNOTE-942 trial, presented at ASCO 2026:

49% reduction in risk of recurrence or death (HR=0.51)
59% reduction in risk of distant metastasis or death (HR=0.41)
At 5-year follow-up

These are striking numbers for an adjuvant therapy. Keytruda alone is already effective; adding intismeran cut remaining risk roughly in half.

What Changes for You

If you have melanoma

Within 18-24 months, your oncologist may offer this. Merck and Moderna are “engaging with regulators on filing submissions” immediately. FDA priority review for a first-in-class adjuvant melanoma therapy with Phase 3 data is likely.

Practical implication: Post-surgery, instead of just Keytruda, you may receive:

Tumor biopsy sent for sequencing
2-4 weeks later: your personalized mRNA vaccine is manufactured
9 doses over ~1 year, alongside standard Keytruda

If you have another solid tumor

Watch the INTerpath program. NSCLC is already in Phase 3. If melanoma results hold across tumor types, the platform becomes standard oncology infrastructure.

If you’re the DIY type

The regulatory path is closing—in a good way. Within 3-5 years, the pipeline that required Conyngham to orchestrate AlphaFold, custom ML, and cold-calling universities becomes a clinical workflow your oncologist orders. You won’t need to build the pipeline; you’ll just need the diagnosis.

The contribution of the Conynghams of the world was proving the concept was executable outside institutional walls. That pressure—showing what’s possible—accelerates institutional adoption.

The Thought Leadership Take

The mRNA platform is becoming general-purpose oncology infrastructure.

COVID vaccines were proof-of-concept for rapid mRNA manufacturing. Cancer vaccines are proof-of-concept for individualized mRNA manufacturing. The same platform that produced billions of COVID doses can now produce millions of custom cancer vaccines—each one unique to a patient.

What changes:

Turnaround time drops. Moderna can manufacture a personalized vaccine in weeks. That gets faster with scale.
Cost drops. First-of-kind is expensive. Millionth-of-kind is cheap. mRNA manufacturing scales.
Tumor types expand. Melanoma is the beachhead. Every solid tumor with sequenceable mutations is a candidate.
Earlier intervention becomes possible. Today: adjuvant (post-surgery). Tomorrow: neoadjuvant (pre-surgery). Eventually: prevention for high-risk individuals.

The regulatory bottleneck is now the rate-limiter, not the science.

Paul Conyngham’s dog Rosie got her vaccine in weeks. A human patient in INTerpath-001 got theirs through a clinical trial. The next generation of patients will get theirs through standard care—but only after FDA approval, insurance coverage negotiations, and clinical guideline updates.

The science is 2-3 years ahead of the system. That gap will close, but the closing is bureaucratic, not technical.

What We Got Right in March

Our original post on the Conyngham case made three claims:

The pipeline is executable by a skilled individual with AI assistance. ✓ Validated by Conyngham’s results.
The approach is scientifically sound—the same one Moderna and BioNTech are pursuing. ✓ Phase 3 success confirms.
The bottleneck is regulatory, not scientific. ✓ Merck and Moderna now enter the regulatory phase with compelling data.

What we hedged on:

Whether n=1 would translate to controlled trials. It did.
Whether combination with checkpoint inhibitors was necessary. Appears so—Keytruda + intismeran outperforms Keytruda alone.

The Honest Caveat

Phase 3 interim analysis is not final approval. The trial continues for overall survival data. Regulatory review takes time. Insurance coverage will be contentious (personalized manufacturing isn’t cheap).

And extrapolating melanoma results to other cancers is hopeful, not guaranteed—each tumor type has different immunogenicity, mutation burden, and microenvironment.

But the trajectory is clear. The first mRNA cancer vaccine just crossed the threshold from experimental to validated. The platform works. The question is no longer if but how fast and how broadly.

This post is a follow-up to our March 2026 piece on Paul Conyngham’s DIY mRNA cancer vaccine for his dog Rosie. If you haven’t read that one, start there for the technical pipeline breakdown.

Source: Merck Press Release, August 19, 2026